You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

ALIMTA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Alimta patents expire, and when can generic versions of Alimta launch?

Alimta is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in ALIMTA is pemetrexed disodium. There are twenty-nine drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the pemetrexed disodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Alimta

A generic version of ALIMTA was approved as pemetrexed disodium by ACCORD HLTHCARE on May 25th, 2022.

  Try a Trial

Drug patent expirations by year for ALIMTA
Drug Prices for ALIMTA

See drug prices for ALIMTA

Recent Clinical Trials for ALIMTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Regeneron PharmaceuticalsPhase 2/Phase 3
Liza Villaruz, MDPhase 2
Hackensack Meridian HealthPhase 2

See all ALIMTA clinical trials

Pharmacology for ALIMTA
Paragraph IV (Patent) Challenges for ALIMTA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ALIMTA For Injection pemetrexed disodium 750 mg/vial 021462 1 2016-10-06
ALIMTA For Injection pemetrexed disodium 1000 mg/vial 021462 1 2012-06-27
ALIMTA For Injection pemetrexed disodium 100 mg/vial 021462 1 2008-07-01
ALIMTA For Injection pemetrexed disodium 500 mg/vial 021462 2 2008-02-04

US Patents and Regulatory Information for ALIMTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-001 Feb 4, 2004 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ALIMTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007 ⤷  Try a Trial ⤷  Try a Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-001 Feb 4, 2004 ⤷  Try a Trial ⤷  Try a Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007 ⤷  Try a Trial ⤷  Try a Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-001 Feb 4, 2004 ⤷  Try a Trial ⤷  Try a Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-001 Feb 4, 2004 ⤷  Try a Trial ⤷  Try a Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ALIMTA

See the table below for patents covering ALIMTA around the world.

Country Patent Number Title Estimated Expiration
Hungary T58335 ⤷  Try a Trial
Argentina 245129 UN METODO PARA LA PREPARACION DE COMPUESTOS DERIVADOS DEL ACIDO (4-HIDROXIPIRROLO ¡2,3-D¿ PIRIMIDIN-3-IL)-L-GLUTAMICO. (N-(PYRROLO(2,3-D)PYRIMIDIN-3-YLACYL)-GLUTAMIC ACID DERIVATIVES) ⤷  Try a Trial
Hong Kong 161495 Improved therapeutic method ⤷  Try a Trial
New Zealand 236385 PYRROLO (2,3-D) PYRIMIDINYLETHYL SUBSTITUTED GLUTAMIC ACID DERIVATIVES, PREPARATORY PROCESSES AND PHARMACEUTICAL COMPOSITIONS THEREOF ⤷  Try a Trial
Spain 2284660 ⤷  Try a Trial
Germany 122005000012 ⤷  Try a Trial
Canada 2051520 METHODE THERAPEUTIQUE (USE OF FOLIC ACID AND ITS DERIVATIVES FOR REDUCING THE TOXICITY OF GAR-TRANSFORMYLASE INHIBITORS) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ALIMTA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0432677 C00432677/01 Switzerland ⤷  Try a Trial FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0432677 SPC/GB05/011 United Kingdom ⤷  Try a Trial PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920
0432677 7/2005 Austria ⤷  Try a Trial PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920
0432677 CA 2005 00008 Denmark ⤷  Try a Trial
0432677 300181 Netherlands ⤷  Try a Trial 300181, 20101210, EXPIRES: 20151209
0432677 91147 Luxembourg ⤷  Try a Trial 91147, EXPIRES: 20151210
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.